Biotechnology company DelMar Pharmaceuticals (NASDAQ: DMPI) has been given a ‘Buy’ rating by Aegis Capital Corp. and a $16 price target (http://dtn.fm/jZlI7). The company was trading at $3.29 on January 11, 2016. To reach that price target, Aegis, in its initiation of coverage, said that it applied a 15x multiple after estimating the company’s 2022 EPS at $3.93, then discounting it by 30%.

DelMar Pharmaceuticals has been developing its lead product candidate, VAL-083, as a chemotherapy for cancer. Specifically, VAL-083 would be used in the treatment of glioblastoma multiforme (GBM), the most common form of a fatal and aggressive brain cancer. VAL-083 is a very different drug from other cancer medications. It avoids the repair activities that enable tumor cells to impede the impact of chemotherapy.

As a result, DelMar has an upcoming phase III trial in refractory GBM and two additional phase II studies anticipated to begin this year. VAL-083 will also be tested in the treatment of solid tumors and lung cancer, with phase I and II trials anticipated in 2017, the report stated. The report was signed by Robert LeBoyer, research analyst at Aegis, who added that Aegis expects DelMar Pharmaceuticals “to be driven” by these trials.

In its report, Aegis said that the phase III study is expected in late 1Q17 and should take place at major medicine centers, aiding enrollment. Further, it said that the Food & Drug Administration (FDA) believes that only one phase III study will be required for VAL-083, following its assessment of the results of completed phase I and II studies.

In 2016, DelMar completed its phase I/II trials of VAL-083, the report stated, and then met with the FDA. The FDA agreed that only one phase III trial would be necessary, because the company would then use a 505(b)(2) regulatory pathway. Aegis notes that this was a ‘significant development’, which may mean phase III results as early as 2019 ahead of approval in 2020.

On January 9, 2017, DelMar Pharmaceuticals received an increase in funding of up to CDN$413,000 from the National Research Council of Canada Industrial Research Assistance Program (NCR-IRAP) to support ongoing research of VAL-083 (http://dtn.fm/iWzk2). In conjunction with the BC Cancer Agency, Vancouver Prostate Centre and the University of British Columbia, research will continue, DelMar Pharmaceuticals announced.

“We are very pleased with NCR-IRAP’s continued support of our non-clinical research of our lead product candidate VAL-083,” Jeffrey Bacha, chairman and CEO of DelMar Pharmaceuticals, noted in the news release.

In its most recent 10-Q filing, DelMar Pharmaceuticals reported cash and cash equivalents of $4,799,033 (http://dtn.fm/5qecY). For the quarter ended June 30, 2016, the company reported to the SEC that it had raised $7.2 million from the sale of convertible preferred stock.

For more information, visit www.DelMarPharma.com

MassRoots, Inc. (OTCQB: MSRT), a company offering cannabis enthusiasts the chance to share their cannabis content while staying connected with news and the latest legislation regarding the drug through a specialized social media platform and iOS application, has shown significant growth in the rapidly developing cannabis industry.

According to a SeeThruEquity update (http://dtn.fm/Y0Har), MassRoots achieved phenomenal growth in 2016, with revenue reaching $794,621 during the first three quarters of 2016, compared to just $63,982 during the same period of the previous year. This performance was attributed to the company’s ability to monetize its users, which increased by 1,140% as compared to the first three quarters of 2015.

The company now has a fan base of over 900,000 users and plans to introduce a range of new features to its platform, fully indexing the network’s public content on Google for search engine optimization purposes. Earlier this week, MassRoots launched an update to its iOS mobile application (http://dtn.fm/W8YeE), which is currently available through the App store. New features include geo-targeted advertisements, in-depth strain and product pages, and revamped reporting and content screening mechanisms.

In addition, MassRoots kicked off 2017 by achieving its strongest cash position in corporate history following the reception of $2 million in proceeds from the exercise of warrants (http://dtn.fm/bUC0G). According to CEO Isaac Dietrich, this capital infusion will allow MassRoots to continue building momentum in the industry. Dietrich has set an intermediate goal of reaching revenue levels similar to industry leaders such as Weedmaps and Leafly, which generated more than $25 million and $15 million in 2016 sales, respectively.

MassRoots’ substantial 2016 growth seems to be widely supported by strong industry trends. With eight states having legalized the recreational use of marijuana, MassRoots is positioned for growth, anticipating an increase in users from a number of states. Currently, the company receives three-quarters of its revenue from California and Colorado, but new markets are expected to emerge.

MassRoots also recently acquired DDDigtal, known as Whaxy, a menu management and online ordering platform for licensed cannabis businesses. In a news release announcing the acquisition (http://dtn.fm/zLsj0), Isaac Dietrich commented, “This acquisition, when completed, will expand MassRoots’ offerings to include a full suite of dispensary software solutions – online ordering, marketing, and real-time inventory management — for cannabis businesses”.

For more information, visit www.MassRoots.com

Moxian, Inc. (NASDAQ: MOXC) continues to buck the trend. Despite the dearth of technology issues in 2016, the company completed a successful best-efforts public offering of 2,501,250 shares of its common stock at a price of $4.00 per share in November 2016, raising $10 million in new capital. Now, Moxian is poised to extend its unique online-to-offline (O2O) platform to a wider market.

Just as the NASDAQ uplisting raises the company’s investor visibility, this infusion of capital will be used to heighten awareness of Moxian and give it a larger footprint. With its new stash of cash, Moxian is set to continue the O2O commercial innovations it has set in motion.

The IPO Intelligence Report from Renaissance Capital (http://nnw.fm/YvX5A) gives some indication of the market skepticism that afflicted the IPO market when Moxian shares were uplisted. Even though the S&P attained record levels in 2016, the capital raised by new issues fell to the lowest level in 13 years. The lack of activity was particularly noticeable in the technology sector, described in the report as the ‘the bread and butter of the IPO market’.

In light of such obvious risk aversion, Moxian’s successful uplisting signals investor endorsement of its strategy. Unlike other O2O companies that seek to add consumers and then rely on that user base to attract merchants, Moxian signs up merchant clients who pay a fee, and it intends to build a Moxian marketplace by bringing together all of those merchant clients’ customers.

The O2O market is one of great potential, particularly in mainland China, where Moxian has its operations. Inc. magazine recently published its reasons on ‘Why O2O Commerce is a Trillion-Dollar Opportunity’ (http://nnw.fm/os89P). In 2014, Jack Ma’s Alibaba (NYSE: BABA) made a $692 million investment in Chinese department store operator Intime Retail Group. It followed that up in 2015 with two major O2O initiatives.

Together with its affiliate, Ant Financial, the internet giant invested $1 million in a joint venture called Koubei. Later that year, Alibaba formed an alliance with the giant brick-and-mortar Chinese electronics chain Suning Commerce Group. Alibaba now owns about 20 percent of Suning, for which it paid $4.63 billion. Suning, in turn, has put out $2.28 billion to acquire 1.1 percent of Alibaba.

Moxian plans to use most of the proceeds from the issue to expand its business in China and throughout Asia. This will include setting up regional and sales offices in first and second tier cities in China, as well as infrastructure investment for the build-out and expansion of offices in these cities. Some part of the funds will be reserved for general corporate purposes and to finance acquisitions of complementary businesses, assets and technologies.

The market opportunities for Moxian are very promising. In 2014, the China Internet Network Information Center reported that there were approximately 618 million internet users throughout Asian countries, representing a penetration rate of approximately 46 percent. Among these internet users, over 90 percent have a social media account. For comparison, just 67 percent of U.S. internet users engage in social media. However, the opportunity in China extends beyond the ability to reach a large target audience. The Data Center of China Internet reports that 38 percent of users claim they are more likely to buy items recommended by other social media users.

Industry analysts estimate that China’s O2O market reached 418 billion yuan (approximately US$67 billion) in 2016. Moxian believes its platform will be able to capture a substantial part of this market very soon.

For more information, visit www.Moxian.com

Net Element, Inc. (NASDAQ: NETE) is targeting two industries on the cusp of greater revolutionary technology investments: hospitality and restaurants. Net Element’s Unified Payments subsidiary recently entered into an agreement with ReservHotel (http://nnw.fm/bO01f), providing technology-driven payment acceptance services. To the restaurant industry, Net Element offers its Aptito cloud-based point-of-sale system (http://nnw.fm/3wmF1).

The hotel industry had a terrific year in 2016, according to STR (http://nnw.fm/kp3Rd). For the week ended December 31, 2016, year-over-year, the industry had nearly flat occupancy, but the payoff was that its average daily rate (ADR) rose 2.2% to $132.79, and its revenue per available room (RevPAR) rose 2.0% to $72.38. Hotels are setting a priority on investing even more in technology to improve profit performance further.

Similarly, the restaurant industry is focusing on technology to launch and then better integrate digital menus with point-of-sale systems. Restaurants are seeking ways to offer more technology to their patrons while also cutting expenses, ensuring more accuracy in billing and improved customer retention.

Net Element’s Aptito is cloud-focused and serves as a solution to the restaurant industry’s point-of-sale issues. It is timed for a fast-growing industry that requires technology to grow more quickly. According to the National Restaurant Association (NRA), the industry did $782.7 billion in sales last year (http://nnw.fm/2Q2yi), but most restaurants are small. The NRA reports that seven out of 10 are single unit operations, making technology even more vital.

In its report, titled ‘Mapping the Restaurant Technology Landscape’ (http://nnw.fm/oI3mK), the NRA finds that, while 81% of restaurants use a point-of-sale or electronic register system and 68% offer Wi-Fi for guests, only 37% of restaurants have online ordering and just 32% offer mobile payments. As a result, 32% say their operations are lagging technology-wise. Just 12% say they have leading-edge technology. Further, 37% of operators say that customer ordering is the most important part of technology development for them over the next five years.

Annika Stensson, director of research communications for the NRA, said four of five restaurant operators believe technology can help make restaurants more productive (http://nnw.fm/g27Ge). However, she added, new technology can also complicate the experience for restaurant customers. “This research highlights the importance that user-friendly, streamlined tech solutions play in creating an innovative restaurant environment and that closing this divide will be a priority for the industry going forward,” Stensson said.

Net Element, Inc., offers Aptito, which is a point-of-sale visual system offering restaurants mobile ordering and digital menus on an iPad app. Additionally, it has a cloud-based mobile app for customers. For restaurants, Net Element also offers an Android-based retail point-of-sale software. The Aptito point-of-sale system allows for seamless integration with the restaurants’ digital menu tablets.

Net Element believes that offering customers a digital menu rather than a paper one will drive more sales, result in fewer mistakes, and cut restaurants’ labor costs. The goal is to achieve more profit, a higher retention rate, customized digital menus, and electronic payment options. The software also allows diners to split checks, merge and move orders, and change tables.

In its latest 10-Q, filed on November 14, 2016, Net Element, reported revenues of $38,963,559 for the nine months ended September 30, 2016, compared to $25,122,250 during the same period of the prior year (http://nnw.fm/Jso65).

For more information, visit www.NetElement.com

Founded in 1999, and with offices in the U.S. and China, ChineseInvestors.com, Inc. (OTCQB: CIIX) acts as a growing Chinese-language investment information and services conduit to the global Chinese investor community. Primarily through its websites, the company provides different levels of investment information, both free and via subscription, including information on the U.S. market and foreign currencies, covering sectors as well as companies, real-time market news and analysis, quotes, charts, and research tools. The company is led by chairman and CEO Warren Wang, COO Brett Roper, CFO Paul Dickman, and Director James Toreson.

The company’s stated mission is to ‘educate and empower individual investors to make their own financial decisions and to achieve their financial goals at any time or place’. Its focus is on what is called the ‘ChineseInvestors Method’, a combination of technical tools, a disciplined investing process, and personalized instruction. It’s an approach that the company’s leadership team hopes to establish as the most widely recognized and used system for educated investing.

In addition, the company offers consulting services to private companies seeking to become public companies, along with advertising and public relations support. Among other things, this provides a unique opportunity for growing companies to reach the large and diverse Chinese investment community, both in the U.S. and globally.

Recently, the company announced (http://dtn.fm/JhZ83) plans to launch the world’s first online cannabidiol (CBD) health products store in the Chinese language, using the domain name of www.ChineseCBDoil.com. Through an agreement with a ‘well-known’ CBD health brand, CIIX will be able to retail nutritional CBD supplements, through both physical and online channels, to the Asian market. China alone has nearly 10 million epilepsy patients, with CBD oil seen as a desired treatment option.

For more information, visit the company’s website at http://www.chinesefn.com/english/indexen.asp

A growing number of human immunodeficiency virus (HIV) patients are in need of new treatment as they start facing issues of drug resistance and their regular therapies are becoming less effective. Unfortunately, new treatment options are scarce to virtually non-existent, as the standard of care for HIV patients remains a combination of different classes of antiretroviral medications at different stages of the infection. Driven by the strong belief that HIV patients, including those newly diagnosed, should receive the treatment they need as soon as possible, Vancouver, Washington-based biotech company CytoDyn Inc. (OTCQB: CYDY) has developed a new therapy, a viral-entry inhibitor called PRO 140, which is currently in Phase 3 clinical trials with very encouraging results so far.

The company has already filed a request with the Food and Drug Administration to grant PRO 140 a Breakthrough Therapy Designation as a therapy for HIV-1 treatment-experienced patients with virologic failure, according to a press release (http://nnw.fm/T2rtg). According to CytoDyn, and based on completed and ongoing clinical trials for the therapy, PRO 140 is a viable treatment options that addresses the unmet medical needs of HIV-1 patients whose regular antiretroviral medication has stopped working. Therefore, granting PRO 140 the designation of Breakthrough Therapy would aid a growing number of heavily treatment-experienced patients in gaining access to a novel therapy to complement or replace their conventional antiretroviral therapy.

If the FDA approves the request and gives PRO 140 the status of Breakthrough Therapy, this will help speed CytoDyn’s Biologics License Application process and bring the company one step closer to releasing the product on the market. The company’s CEO and President, Dr. Nader Pourhassan, said he was hopeful that the FDA would approve the request, as PRO 140 has successfully demonstrated its value as part of a combination therapy, the population for which this Breakthrough Therapy was filed. Moreover, PRO 140 has shown great results as a single agent therapy for some HIV patients (not all) with the R5 strain of human immunodeficiency virus.

Pourhassan said his company has already received several requests to allow patients continued access to PRO 140 so as to maintain viral suppression after the end of treatment in the Phase 3 combination therapy study. He explained that seven patients have already joined a rollover study to continue deriving clinical benefits from the therapy at the end of the 25-week Phase 3 study. And in the single agent therapy study, CytoDyn currently has 10 HIV patients who’ve demonstrated suppressed viral load for more than two years.

Belonging to a new class of HIV/AIDS therapies called viral entry inhibitors and designed to protect healthy cells from infection, PRO 140 works by blocking the HIV co-receptor CCR5, therefore preventing viral entry. All clinical trials conducted so far concluded with encouraging results and have indicated that the new therapy does not have a negative impact on the normal immune functions associated with CCR5. A total of seven Phase 1 and 2 clinical trials have indicated that the new therapy can significantly reduce viral burden, while the recent Phase 2b trial showed that PRO 140 can actually prevent viral escape during a seven-month hiatus in conventional antiretroviral drug therapy.

For more information, visit the company’s website at www.CytoDyn.com

Before the opening bell, Net Element, Inc. (NASDAQ: NETE) announced that its PayOnline subsidiary has entered into a new partnership with Sutochno.ru, Russia’s premier C2C short-term booking service, through which PayOnline will be providing online payment acceptance services for the platform. Similar to Airbnb, Sutochno.ru gives users the tools to book short-term accommodation in markets across Russia. The site currently features more than 70,000 property listings, and it attracted over 700,000 guests in 2016. Sutochno.ru differentiates itself from Airbnb by offering a more attractive pricing model that eliminates commission charges for guests and minimizes fees for hosts.

Moving forward, PayOnline’s advanced payment technologies are expected to play a key role in Sutochno.ru’s ongoing efforts to add convenience and security for its customers while simultaneously enhancing the overall user experience. In this morning’s update, Yuri Kuznetsov, founder of Sutochno.ru, noted a collection of payment needs that he expects to be addressed through the PayOnline partnership, including “pre-authorization, escrowing and payment processing via all types of cards.”

“We are honored to see Sutochno.ru amongst our merchants; PayOnline has invested heavily in product development, and it is rewarding to see how merchants can utilize the capabilities of our platform to meet their business needs and provide an excellent experience to the end consumer,” Marat Abasaliev, chief executive officer of PayOnline, stated in this morning’s news release.

This morning’s update marks the second time in less than a week that Net Element, through its subsidiaries, has secured an agreement with a client operating in the booming global travel market. Last Friday, the company announced that its Unified Payments subsidiary had entered into an agreement and launched payment acceptance services for ReservHotel, a leading provider of travel distribution and booking solutions for hotels worldwide. Both partnerships highlight the marketability of Net Element’s capabilities as a global payment acceptance platform, particularly as it relates to cross-border transactions and complementary services.

Outside of the travel sector, Net Element has continued to establish its position on the international stage through partnerships with market leaders across a number of other industries. Last month, the company’s PayOnline subsidiary announced the launch of a payment acceptance module for Telegram, a popular cloud-based mobile and desktop instant messenger application. This first-of-its-kind payment service was made available upon launch for clients of VTB Insurance, a leading insurance provider in Russia, further strengthening Net Element’s strategic position in Russia’s rapidly developing electronic payments market. PayOnline currently provides payment acceptance services to more than 3,000 online, multi-channel merchants and service providers in the Commonwealth of Independent States, Europe and Asia.

For more information, visit www.NetElement.com

GainClients, Inc. (OTC: GCLT) is disrupting the real estate marketing and advertising industry. Its GCard mobile technology platform ‘allows the loan originator, the real estate sales person, or the “title guy” to succeed in this marketplace’. In an interview with RedChip (http://dtn.fm/ez6tY), CEO of GainClients, Ray Desmond, discussed the concepts behind his company’s business model.

GainClients, it appears, is attempting to monetize the store of data and knowledge amassed by CEO Ray Desmond over his 36 years in the real estate industry.

“We’ve created our daily opportunities product that allows us to catch that person that’s selling their house that was our past client… that we did the loan for… now they’re selling their house.”

GainClients wants to be the early bird that catches the worm.

“And we are basically catching them waving their hand as soon as they list that property on the market and so, immediately, we can… contact that person through our GCard, which allows that person to not only get first dabs at that lending possibility, get first dabs at that buyer coming in to buy the house and get in front of a new realtor… But also allows the consumer through our GCard to accept our offer and to go out and learn about shopping and be able to shop with his home search… It works for everyone.”

The GCard is a mobile relationship builder for the real estate industry. Through it, real estate agents, lenders, title search personnel, escrow professionals, and buyers and sellers can all connect on a smart phone-accessible mobile network. A professional can invite his or her partners, clients, and others to join his or her network.

The GCard has tools for the professional that will track network activity, as well as tools for the consumer, such as a mortgage calculator. It also offers National IDX Home Search and Home Scoop National Data Facts, and it will post loan rates, send newsletters to clients, and has texting capability. The GCard has been touted as the real estate professional’s new business card… with a 7-day scorecard to track clients’ activity. It’s designed to help real estate professionals succeed by sharing data on listings, loan services, and title and other due diligence services.

The GCard has a large potential customer base. Real estate transactions can involve a large number of professionals, including a realtor or real estate agent, a listing agent, a buyer’s agent, a loan officer, an appraiser, a home inspector, an insurance agent, an attorney, an escrow or closing officer and a title company representative. The system is already proving its worth.

“Opportunities are delivered every day to all the loan officers in a mortgage company… there are many large mortgage companies out there with a lot of past customers. And we’ve been doing this for years but not in this fashion. This is going to be disruptive because about 41 percent of these opportunities we found are turning into actual closed loans. So, that’s a pretty large number.”

It is indeed. CEO Desmond has, obviously, done the math. He sees the essential value proposition of GainClients in four factors:

• Large revenue potential
• Ongoing flow of warm leads
• High close ratio
• First-mover advantage

Adding that large revenue potential leads to higher share value, he notes that GCLT is now below historic levels. This, he opines, is because the company has not ‘made any big announcements there and we don’t have the revenue yet’. GCLT has been as high as $0.175 as recently as September 2016. The stock currently trades at $0.04.

For more information, visit the company’s website at www.gainclients.com

Let us hear your thoughts: GainClients, Inc. Message Board

Cytosorbents Corp. (NASDAQ: CTSO), a critical care-focused immunotherapy company engaged in the research, development, and commercialization of medical devices, most prominently its platform blood purification technology that incorporates a proprietary adsorbent polymer technology, recently pre-announced unaudited results (http://dtn.fm/bKG3F) for fiscal 2016 ahead of its Form 10-K filing.

Cytosorbents expects to announce between $8.1 and $8.3 million in Cytosorb sales for the whole of 2016. This equates to more than double the total from the previous year. Cytosorb is the company’s flagship product, a blood filter that helps treat deadly inflammation in critically-ill and cardiac surgery patients across the globe.

In addition to this, the company predicts product sales for the fourth quarter of 2016 to range between $2.5 and $2.7 million, compared to just $1.5 million during the fourth quarter of 2015. This will take Cytosorbents to its sixth consecutive quarter reporting record sales, with the result representing a 20% increase as compared to the third quarter of 2016.

Cytosorbents Corp. had its ‘Buy’ rating reaffirmed by equities and research analysts at HC Wainwright, B. Riley, Maxim Group, Brean Capital, and Aegis Capital Corp., all according to Daily Quint (http://dtn.fm/80qqY). Currently, the consensus target price for the company is $15.05 per share. Not only this, Advisor Group, Inc. raised its position in Cytosorbents’ stock by over 1% during the third quarter, giving it ownership of 1.20% of the company’s stock worth over $1.9 million. To view the latest Aegis update, visit http://dtn.fm/YMJf3.

Cytosorbents Corp. also announced that it is expanding its partnership with Fresenius Medical Care (FMC) (http://dtn.fm/biF1L), the world’s largest dialysis company, increasing the commitment to a three-year renewal and a guaranteed minimum order of Cytosorb. The expansion also includes the addition of a new co-marketing agreement for worldwide Cytosorb markets.

For more information, visit www.Cytosorbents.com

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a company in the business of developing and commercializing MicroRNA-based and other molecular diagnostics, recently had its ‘Buy’ rating restated by Aegis Capital Corp. (http://dtn.fm/l0Yk0) with a price target of $3.50 per share. This was based on Aegis’ 2017 revenue estimate of $17.7 million with a multiple of 4X. The company update was released after Rosetta Genomics Ltd. announced a new collaboration to determine biomarkers that can predict response to Opdivo, a PD-1 immunotherapy.

In addition to the above, Aegis Capital Corp. announced expectations for Rosetta Genomics’ cash deliverables to be over $9 million by the end of this year after the company completed a financing with stock and convertible debentures of approximately $5 million. This is accompanied by the fact that Rosetta Genomics continues to expand its portfolio of diagnostic tests through collaborations, allowing it to grow its business and expand its client base.

The company reported an increase in revenue from $2.3 million in 1H15 to $5 million during the first six months of 2016. This has been put down to a growing demand for RosettaGX Reveal for thyroid, for which revenues were expected to reach approximately $1.5 million by the end of September 30, 2016, according to the report. Not only this, total expenses were lower than Aegis’ estimates, showcasing the company’s ability to efficiently manage its cash.

Since Aegis initiated coverage on Rosetta Genomics, the company has grown from a single diagnostic to a portfolio covering solid tumors, urology, and thyroid cancer. Aegis estimates the company’s product revenue to be $10.8 million for the full year with allowance for variations in revenue recognition and COGS, which is currently estimated at 85% of the revenue level seen in previous quarters.

Aside from the company’s ability to continue to make progress in product development, sales growth, and financial advancements, Aegis expects Rosetta to continue to increase its sales and customer base. According to Community Financial News (http://dtn.fm/xES6P), institutional investor Morgan Stanley recently increased its stake in Rosetta Genomics Ltd. by 15%, giving it ownership of just under 338,000 shares of the company’s stock. Hedge funds and institutional investors now own just below 4.3% of the company’s stock.

For more information, visit www.RosettaGx.com